Literature DB >> 19489687

Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease.

John H Peters1, Tammy Greasby, Nancy Lane, Anthony Woolf.   

Abstract

Surrogate markers to detect vasculitic processes prior to organ compromise are lacking. To determine if specific populations among the fibronectin (FN) family of alternatively spliced proteins correlate with parameters of vasculitis in at-risk patients, we retrospectively evaluated the association of plasma levels of total FN (TFN) and FN bearing the alternatively spliced EIIIA segment (A(+)FN) with clinical vasculitis status and with levels of two putative vasculitis markers (C-reactive protein (CRP) and von Willebrand factor) in a previously studied cohort of 27 patients with systemic inflammatory disease. We found that the percentage of TFN composed by A(+)FN (%A(+)) and A(+)FN, but not TFN, correlated with plasma levels of CRP, the prototypic inflammation biomarker used to detect vasculitis. These findings suggest that different FNs may confer distinct clinical information, and that their simultaneous measurement merits further investigation in our efforts to identify soluble biomarker systems to detect vasculitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19489687      PMCID: PMC2746117          DOI: 10.1080/13547500902836032

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  34 in total

Review 1.  C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?

Authors:  Gavin J Blake; Paul M Ridker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-11       Impact factor: 3.619

2.  Plasma fibronectin is synthesized and secreted by hepatocytes.

Authors:  J W Tamkun; R O Hynes
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

Review 3.  Von Willebrand factor in polymyalgia rheumatica and giant cell arteritis.

Authors:  A C Uddhammar
Journal:  Clin Exp Rheumatol       Date:  2000 Jul-Aug       Impact factor: 4.473

Review 4.  Vasculitis: contemporary perspectives.

Authors:  Anita Krishnamurthy; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Compr Ther       Date:  2006

5.  Semicarbazide-sensitive amine oxidase in pre-eclampsia: no relation with markers of endothelial cell activation.

Authors:  J Marko Sikkema; Arie Franx; Rob Fijnheer; Peter G J Nikkels; Hein W Bruinse; Frans Boomsma
Journal:  Clin Chim Acta       Date:  2002-10       Impact factor: 3.786

6.  Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis.

Authors:  Michelle H Tan; Zhengwu Sun; Sarah L Opitz; Tracy E Schmidt; John H Peters; Elizabeth L George
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

7.  Plasma levels of fibronectin bearing the alternatively spliced EIIIB segment are increased after major trauma.

Authors:  John H Peters; Grace A Loredo; Ge Chen; Richard Maunder; Theodore J Hahn; Neil H Willits; Richard O Hynes
Journal:  J Lab Clin Med       Date:  2003-06

8.  Studies on cold insoluble globulin. I Concentrations in citrated plasma in rheumatic disorders.

Authors:  O Fyrand; E Munthe; N O Solum
Journal:  Ann Rheum Dis       Date:  1978-08       Impact factor: 19.103

9.  Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.

Authors:  Mar Castellanos; Rogelio Leira; Joaquín Serena; Miguel Blanco; Salvador Pedraza; José Castillo; Antoni Dávalos
Journal:  Stroke       Date:  2004-05-27       Impact factor: 7.914

10.  Fibronectin is produced by blood vessels in response to injury.

Authors:  R A Clark; J H Quinn; H J Winn; J M Lanigan; P Dellepella; R B Colvin
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

View more
  1 in total

1.  Changes in plasma fibronectin isoform levels predict distinct clinical outcomes in critically ill patients.

Authors:  John H Peters; Mark N Grote; Nancy E Lane; Richard J Maunder
Journal:  Biomark Insights       Date:  2011-05-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.